Business Context and Reporting Period
This Form 8-K reports on the 2015 Annual Meeting of Stockholders held by Pieris Pharmaceuticals, Inc. on June 30, 2015. The registrant is incorporated in Nevada and maintains its principal executive offices in Freising-Weihenstephan, Germany. Note: The request metadata references "Palvella Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Pieris Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
The filing details the outcomes of two proposals submitted to security holders:
- Shareholder Participation: Of 29,429,522 shares outstanding as of the May 8, 2015 record date, a quorum of 18,998,391 shares was present.
- Proposal 1 (Election of Directors): Dr. Jean-Pierre Bizzari was elected as a Class I Director to serve until the 2018 Annual Meeting.
- Votes For: 17,563,360
- Votes Withheld: 1,056,660
- Broker Non-Votes: 378,371
- Proposal 2 (Ratification of Auditors): The appointment of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft as the independent registered public accounting firm for the fiscal year ending December 31, 2015, was ratified.
- Votes For: 18,998,378
- Votes Against: 13
- Votes Abstained: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the correct registrant name (Pieris Pharmaceuticals, Inc.) against the metadata provided (Palvella Therapeutics, Inc.).
- Confirm the tenure of the newly elected director, Dr. Jean-Pierre Bizzari, through the 2018 Annual Meeting.
- Note the near-unanimous ratification of Ernst & Young as the independent auditor.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.